Cerium ACTH-PMN-301

PMN

Comparing the safety and efficacy of SNP-ACTH (1-39) Gel compared to Rituximab and FDA approved biosimilars in adults with primary membranous nephropathy (PMN) in a Two-Phase Adaptive Trial Design

Phase 3 Superiority Study

Chinook CHK01-03

IgAN on SGLT2i

Study of Atrasentan in subjects with IgA Nephropathy on Sodium-glucose Cotransporter-2 Inhibitors (SGLT2i)

Randomized, Double-Blind, Placebo-Controlled, Crossover

Eli Lilly J1I-MC-GZBO

Atherosclerotic Cardiovascular Disease, Chronic Kidney Disease

Investigate the effect of retatrutide on the incidence of major adverse cardiovascular events and the decline in kidney function in participants with body mass index >= 27 kg/m^2 and atherosclerotic cardiovascular disease and/or chronic kidney disease

Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven

Novartis CVAY736K12301

SIRIUS-LN

Evaluate the efficacy, safety, and tolerability of ianalumab on top of standard-of-care therapy in participants with active lupus nephritis (SIRIUS-LN)

Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Phase 3

Otsuka 417-201-00007

IgAN

Evaluate the efficacy and safety of Sibeprenlimab administered subcutaneously in subjects with Immunoglobulin A Nephropathy

Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled

Pathalys PP3002

PATH-1

Evaluating the efficacy and safety of dose-titrated PLS240 in the treatment of secondary hyperparathyroidism in individuals with end stage kidney disease on hemodialysis (PATH-1) with an open-label extension

Phase 3 Randomized, Double-Blind, Placebo-Controlled

Vertex VX21-147-301

APOL1

Evaluate the efficacy and safety of VX-147 in adult and pediatric subjects with APOL1-mediated Proteinuric Kidney Disease

Phase ⅔ Adaptive, Double-blind, Placebo-Controlled